E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
To protect healthy male and female children aged 1 to 11 years old included against hepatitis A and B.
|
|
E.1.1.1 | Medical condition in easily understood language |
Infection of the liver
Persistent Jaundice
Liver failure
Liver cancer
|
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate anti-HAV and anti-HBs antibody persistence at Year 6 (i.e. Month 72), Year 7 (i.e. Month 84), Year 8 (i.e. Month 96), Year 9 (i.e. Month 108) and Year 10 (i.e. Month 120) after the first vaccine dose of two-dose pri-mary vaccination.
To evaluate the immune memory (after a primary two-dose schedule of TWINRIX™ ADULT 720/20 vaccine) in subjects who became seronegative for anti-HAV antibod-ies (i.e. titres < 15 mIU/ml) or lost seroprotective titres for anti-HBs antibodies (i.e. titres < 10 mIU/ml) at Year 6, 7, 8, 9 or 10 and subjects who received an additional vaccine dose (administered between 6 to 12 months after the Year 10 time point).
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Persistance phase:
Subjects who had received at least one dose of the study vaccine in the primary study HAB-076.
Written informed consent was obtained from the subject and/ or parents or guardians of the subject before the blood-sampling visit of each follow-up visit.
Challenge dose:
Subjects who became seronegative for anti-HAV antibod-ies or had anti-HBs antibody concentrations < 10 mIU/mL at long-term blood sampling time-points up to Year 10 were eligible to receive a challenge dose of the appropriate vaccine 6 to 12 months after the Year 10 visit.
|
|
E.4 | Principal exclusion criteria |
-History of previous vaccination against hepatitis A or B.
-History of hepatitis.
-History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease.
-Any acute disease at the moment of entry.
-Hepatomegaly, right upper quadrant abdominal pain or tenderness.
- Any chronic drug treatment, including any treatment with immunosuppressive drugs, which in the investigator's opinion, precludes inclusion into the study.
- History of allergic disease likely to be stimulated by any component of the vaccine.
- Administration of immunoglobulins within six months of the first vaccination or planned during the study period.
-Receipt of any other vaccine within 1 week of a dose of the study vaccine (period extending from 1 week before to 1 week after a dose of vaccine).
Simultaneous participation in any other clinical trial, the only exception being involvement in long-term follow-up in another vaccine trial. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immunogenicity
Anti-HAV seropositivity rates and GMCs (calculated on the seropositive subjects).
Anti-HBs seropositivity rates, proportion of the subjects with antibody concentrations >=10 mIU/mL and GMCs (calculated on the seropositive* subjects) at all LTFU time-points.
Safety
SAEs that are determined by the investigator to have a causal relationship to primary vaccination, any event related to a lack of vaccine efficacy (i.e. hepatitis A or hepatitis B infection) or SAEs that are related to study participation (blood sampling). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At all LTFU time-points (At Years 6, 7, 8, 9 and 10). |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 10 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |